CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

All Posts

Our immune system has the ability to detect and fight infectious pathogens. It can also detect when normal cells become cancerous and kill those cells, preventing cancer progression. But over time, cancers can evolve and evade the immune response.

Researchers have been investigating several potential avenues to counter tumor immunosuppression and re-activate the immune system. One of these is CAR-T therapy, which is designed to harness the potent cytotoxicity of T cells by re-engineering their surface receptors to recognize and attack tumors.

Part One:

 

Part Two:

 

Chris Sumner
Chris Sumner
Chris Sumner was a writer at CST. When he's not reading/writing about curing disease, he's hiking in the woods, playing guitar, or searching for the world's best lobster roll.

Recent Posts

Mapping RNA-Protein Interactions with RBP-eCLIP: Powering Discovery in RNA Biology

Guest author Dr Vince Harjono is an Application Scientist Manager at Eclipsebio. CST and Eclipsebio have ...

Key Epithelial-Mesenchymal Transition (EMT) Markers in Cancer

EMT, or epithelial-mesenchymal transition, is a biological process in which epithelial cells gain the abi...
Susan Keezer, PhD Jun 4, 2025

Targeting the Tumor Microenvironment: Key Markers of the ECM

In recent years, cancer researchers have started paying closer attention to the extracellular matrix (ECM...
Susan Keezer, PhD May 28, 2025